## Thesis Review Summary

Our portfolio strategy continues to center on **uncorrelated, catalyst-driven small caps** aimed at outsized alpha. After this week’s adjustments, we have a refined set of holdings that align with our mandate and risk controls:

* **Biotech/Rare Disease Segment:** We are invested in three life science companies, each with independent catalysts. **Atara Biotherapeutics** (ATRA) is approaching an FDA verdict that could be transformative – approval of Tab-cel would validate its allogeneic cell therapy platform and likely propel the stock higher[\[1\]](https://www.cgtlive.com/view/fda-accepts-atara-biotherapeutics-resubmission-bla-tabelecleucel#:~:text=Notably%2C%20the%20BLA%20resubmission%20was,for%20the%20aforementioned%20treatment%20setting). **Fortress Biotech** (FBIO) offers a “hidden asset” play: an imminent FDA decision on a rare pediatric disease drug. A positive outcome not only yields potential revenue but a Priority Review Voucher that could bring in a substantial one-time cash sale[\[24\]](https://www.globenewswire.com/news-release/2025/12/15/3205379/0/en/Fortress-Biotech-and-Cyprium-Therapeutics-Announce-FDA-Acceptance-of-CUTX-101-NDA-Resubmission.html#:~:text=Pursuant%20to%20the%20transaction%20with,and%20sales%20milestones%20from%20Sentynl), which the market may not have fully priced in. **Anixa Biosciences** (ANIX) provides longer-term exposure to innovative cancer immunotherapies (a breast cancer vaccine and ovarian cancer CAR-T). It recently proved its vaccine concept in humans, an achievement that de-risks the program scientifically[\[6\]](https://ir.anixa.com/press-releases/detail/1107/anixa-biosciences-announces-positive-phase-1-data-for#:~:text=Final%20Phase%201%20findings%20showed,com%2Fevents). While ANIX won’t have a binary event next week, it underpins the portfolio’s pipeline-driven growth potential into 2026\. These biotech positions are deliberately weighted modestly and carry predefined stops – this ensures that any single clinical/regulatory failure would only dent our portfolio, while successes could significantly lift our returns. We like that each biotech’s fate is idiosyncratic: one is cell therapy for post-transplant cancer, another is a pediatric genetic disease treatment, and the third is oncology immunotherapy – **diversification even within our biotech sleeve**. This way, positive news in one won’t necessarily be negated by negative news in another. The coming weeks (especially mid-January) will test this thesis, and we are positioned to react nimbly to either outcome.

* **Clean Energy/Climate Tech Segment:** We have repositioned our green tech exposure to focus on **profitable or clearly improving businesses** riding strong policy-driven tailwinds. We exited Sigma Lithium – while we still believe in the lithium supercycle (EV demand growth), Sigma had become an outsized bet with weakening financial footing. Instead, we’ve doubled down on more fundamental value plays. **Hudson Technologies** remains a cornerstone: it’s fundamentally profitable, with a niche dominance in refrigerant recycling that benefits from global warming mitigation efforts (HFC phaseout, low-GWP refrigerants)[\[3\]](https://markets.businessinsider.com/news/stocks/hudson-technologies-announces-accretive-acquisition-of-refrigerants-inc-1035654806#:~:text=%E2%80%9CThe%20AIM%20Act%E2%80%99s%20continued%20phase,view%20and%20capital%20allocation%20strategy). Hudson’s steady cash generation and even stock buybacks provide downside cushioning, which is rare in micro-caps. **Aemetis (newly added)** brings a compelling turnaround story. It anchors our renewable fuels theme – Aemetis is converting policy incentives (like carbon credits and tax grants) into tangible improvements in its cost structure. By mid-2026, Aemetis expects to radically increase cash flow[\[26\]](https://www.aemetis.com/aemetis-receives-authority-to-construct-air-permits-for-mvr-project-at-california-ethanol-plant/#:~:text=The%20MVR%20project%20is%20expected,transferable%20Section%2045Z%20tax%20credits), potentially moving from a net loss to a healthy profit margin. We anticipate that as this execution becomes evident, the market will rerate AMTX from a penny stock to a legitimate green energy success story. Importantly, Aemetis’s fate is not tied to commodity luck but to engineering and regulatory follow-through – which are more predictable. **FuelCell Energy** complements the theme as our high-upside speculative pick: it’s our levered play on the clean energy revolution intersecting with the AI boom. FCEL’s recent pivot to powering data centers addresses an urgent need (reliable, clean on-site power) and gives the company a viable growth avenue[\[40\]](https://www.nasdaq.com/articles/lagging-leading-fuelcell-energys-strategic-pivot#:~:text=While%20earnings%20sparked%20the%20rally%2C,day%2C%20seven%20days%20a%20week)[\[41\]](https://www.nasdaq.com/articles/lagging-leading-fuelcell-energys-strategic-pivot#:~:text=isn%27t%20blowing,afford%20downtime). With a massive backlog and improved balance sheet, FuelCell has the runway to pursue these opportunities without near-term dilution[\[5\]](https://www.nasdaq.com/articles/lagging-leading-fuelcell-energys-strategic-pivot#:~:text=secondary%20stock%20offering%20to%20fund,end%20financial%20update). It is still loss-making, but the trajectory is toward breakeven, and any big contract win could accelerate that. We keep this position smaller due to volatility, but it’s an important part of our **“lottery ticket” allocation for outsized gains**. Overall, our clean tech holdings (HDSN, AMTX, FCEL) are grounded in different sub-sectors – industrial gases/recycling, biofuels, and fuel cells – reducing single-factor risk. All are buoyed by secular trends in decarbonization and energy transition, backed by government incentives or corporate demand.

* **Portfolio Balance and Outlook:** By shedding SGML, we resolved an over-concentration issue and brought all positions back into alignment with our sub-$500M market-cap focus (aside from FCEL’s borderline size, which we’re monitoring). Our portfolio’s **Sharpe ratio (annualized \~3.31) and Sortino (\~10.59)** remain very strong, reflecting our ability so far to capture high returns (we’re beating the S\&P by a wide margin) while managing downside. This is partially due to our heavy cash buffers earlier and timely profit-taking on spikes. Moving forward, the portfolio is a bit more invested (about 78% equities / 22% cash post-trades), but still reasonably liquid. We expect **volatility** to pick up as our catalyst dates hit – this is anticipated and part of the design. The current max drawdown is \~20.8%[\[42\]](https://investors.atarabio.com/news-events/press-releases/detail/376/atara-biotherapeutics-announces-u-s-fda-acceptance-and#:~:text=News%20%26%20Events%20,), which occurred back in late September; we have since recovered significantly. We will strive to keep any future drawdowns shallower by employing stops and quickly cutting losers. Each week, we’ll re-evaluate every holding: does it still have a catalyst ahead? Is the thesis on track? If not, we won’t hesitate to rotate to better opportunities or move to cash. Conversely, we will let our winners run when thesis momentum is building. The coming week (Week 15) is mostly about positioning and monitoring, whereas Week 16-17 will likely see resolution of key biotech bets – by then, we’ll either be cashing in on big wins or stopping out to protect capital. In either case, our disciplined approach should preserve the strong **alpha** we’ve generated (note: our CAPM alpha vs the S\&P is extraordinarily high[\[37\]](https://www.rttnews.com/corpinfo/fdadetail.aspx?id=2469#:~:text=Atara%20Biotherapeutics%20Inc,FDA%20declined%20to%20approve), albeit on a short sample). Our goal is to maintain this edge by sticking to catalyst-rich names that can move independently of the market.

In summary, we have a well-curated micro-cap portfolio that balances **short-term catalysts** (FDA approvals, contracts) and **long-term theses** (efficiency upgrades, industry shifts). We’ve tightened the portfolio to six key stocks plus cash, each with a clear reason to be held. Going into the new year, we are optimistic about our positions yet prepared for all outcomes. The emphasis remains on risk-adjusted decisions: every move is backed by deep research (as evidenced by the sources cited for each thesis) and every position has a defined exit strategy. This disciplined, research-intensive approach is how we plan to continue outperforming the benchmarks while managing the inherent volatility of our niche.

